Click here to close now.

Welcome!

iPhone Authors: Pat Romanski, Carmen Gonzalez, Elizabeth White, Liz McMillan, Dana Gardner

News Feed Item

Roche anuncia la indicación de marca CE expandida para la prueba del VPH cobas® 4800

- Roche anuncia la indicación de marca CE expandida para la prueba del VPH cobas® 4800 apoyando su uso para la exploración primaria del cáncer cervical  

-- La detección del ADN del VPH encuentra la enfermedad que no detecta la citología Pap

PLEASANTON, California, 28 de noviembre, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ha anunciado hoy una indicación de marca CE expandida para la prueba del VPH cobas® 4800. La indicación recientemente expandida para la prueba del VPH cobas® 4800 como exploración primaria significa que ya no se requiere la citología Pap como un test conjunto o previo en países que acepten una marca CE. La infección persistente con el papilomavirus humano es la principal causa de cáncer cervical en mujeres. La indicación expandida está respaldada por los datos que se presentarán en la International Papillomavirus Conference, del 30 de noviembre al 6 de diciembre de 2012, en San Juan, Puerto Rico.

"La prueba del VPH ofrece un nivel más sensible de exploración que la prueba Pap. Mientras que la citología busca células anormales, una prueba VPH busca la presencia de ADN del VPH", dijo Eduardo Franco, director, de la División de Epidemiología del Cáncer, McGill University, Montreal, Canadá. "La prevalencia de VPH significa que muchas mujeres pueden tener resultado positivo, de modo que es importante identificar también las que más riesgo tienen de progresar a un cáncer cervical. La genotipificación para los tipos de VPH 16 y 18 ofrece una especificidad adicional suficiente para identificar a las mujeres de más riesgo y ahorra al resto posibles intervenciones innecesarias. Los dos genotipos de VPH, 16 y 18, suponen el 70% de los casos del cáncer cervical".

La prueba del ADN del HPV se ha utilizado más tradicionalmente como una co-prueba o test reflejo para un resultado citológico anormal o límite. Mientras que la exploración citológica ha reducido drásticamente la prevalencia de cáncer cervical en las últimas décadas, tiene limitaciones debido a la baja sensibilidad y la naturaleza subjetiva de la interpretación de los resultados. Sin embargo, los estudios muestran que la prueba del ADN del VPH es más sensible que la citología al detectar enfermedad, algo importante en una exploración de primera línea. En el estudio de referencia ATHENA, se muestra que la prueba del VPH cobas® 4800 encuentra enfermedad que no detecta la citología: 1 de cada 10 mujeres que dieron positivo en los genotipos de VPH 16 y 18 por la prueba del VPH cobas® 4800 de Roche ya presentaban evidencia de pre-cáncer cervical, aunque la citología fuera normal.  

Aproximadamente 275.000 mujeres en el mundo mueren de cáncer cervical cada año, y muchos países están en proceso de realizar pruebas de ADN del VPH como una sustitución para la citología. "Pasar al uso de la prueba del VPH cobas® 4800 como exploración primaria permite a los países implementar estrategias que detecten más enfermedad con menos intervenciones médicas, permite a los médicos tratar mejor a sus pacientes y reduce el coste económico para el sistema sanitario", dijo Paul Brown, jefe de Roche Molecular Diagnostics.

La prueba del VPH cobas® 4800 es la única prueba aprobada por la FDA validada clínicamente que simultáneamente proporciona resultados sobre los conocidos genotipos "de alto riesgo" y resultados individuales sobre los genotipos de mayor riesgo, HPV 16 y HPV 18, dando tres resultados en solo una prueba. La prueba del VPH cobas® 4800 tiene un proceso del flujo de trabajo de preparación de muestra totalmente automatizado, y funciones de eficiencia únicas que permite un mayor rendimiento, haciéndolo adecuado para programas de exploración de alto volumen.

"Como organización comprometida con la salud de la mujer, Roche Diagnostics se dedica a mantener a las mujeres sanas y mejorar el cuidado a los pacientes", dijo Paul Brown. "Combinada con nuestros productos desde la adquisición empresarial de mtm anunciada el año pasado, Roche cuenta con una amplia cartera de prevención del cáncer cervical que redefine la exploración del cáncer cervical y asesora con más efectividad sobre las decisiones de tratamiento a pacientes". 

Conferencia internacional sobre el virus del papiloma
Roche presentará los datos que respaldan la indicación expandida de la prueba de VPH cobas® 4800 así como la cartera del cáncer cervical más amplia de Roche en la Conferencia Internacional del Virus del Papiloma, del 30 de noviembre al 6 de diciembre de 2012 en San Juan, Puerto Rico.

Roche Satellite Symposium:  Translating Science into Primary Screening Practice
Lunes, 3 de diciembre, 12:30 PM1:45 PM, Puerto Rico Convention Center, Ballroom B

Primary HPV screening: Impact of varying the age of initiation on the performance of screening
Wright TC, Cox JT, Sharma A, Apple R, Behrens CM
Martes, 4 de diciembre, 2:00PM - 3:30PM, Room 208

3 Year cumulative incidence rates for high-grade cervical disease: Interim analysis from the ATHENA study
Castle PE, Wright TC, Stoler, MH, Zhang, Behrens CM
Martes, 4 de diciembre, 2:00PM- 3:30PM, Room 208

Intra-laboratory variation in the performance of liquid-based cytology; insights from ATHENA
Stoler MH, Wright TC, Apple R, Sharma A, Behrens CM
Martes, 4 de diciembre, 5:30PM - 7:30PM (Poster Session)

Acerca del estudio ATHENA
El estudio ATHENA de referencia de Roche para la prueba cobas® 4800 HPV es el mayor estudio de registro basado en EE.UU. para la exploración del cáncer cervical, incluyendo más de 47.000 mujeres.  

Acerca de la prueba de VPH cobas® 4800 y el sistema cobas® 4800

La prueba de VPH cobas® 4800 es una prueba cualitativa in vitro para detectar el virus del papiloma humano (VPH) en muestras de pacientes. La prueba utiliza la amplificación del ADN diana mediante reacción en cadena de la polimerasa (PCR) y la hibridación de ácidos nucleicos para detectar en un único análisis catorce genotipos de VPH de alto riesgo; identifica específicamente 14 tipos de VPH de alto riesgo, y al mismo tiempo detecta genéricamente los otros genotipos de alto riesgo (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 y 68). Actualmente está disponible en los EE.UU. y en todos los países que reconocen la marca CE.

El sistema cobas® 4800 está diseñado para ofrecer nuevos niveles de eficiencia analítica y relevancia diagnóstica. El sistema ofrece una automatización completa que no requiere la presencia de un operador y puede realizar hasta 282 pruebas en menos de 12 horas, lo que permite un análisis rápido de pruebas de cribado de infección por VPH que satisface las necesidades de la mayoría de laboratorios de análisis clínicos.

Acerca del virus del papiloma humano y el cáncer cervical
La infección persistente por el virus del papiloma humano (VPH) es la causa principal del cáncer de cuello de útero (cáncer cervical) en las mujeres; el VPH está implicado en más del 99% de los casos en todo el mundo. Según el Instituto Nacional del Cáncer estadounidense, cada año se dan en ese país 12.200 nuevos casos de cáncer cervical y se producen 4.210 fallecimientos por esa enfermedad. La Organización Mundial de la Salud estima que en todo el mundo son unos 470.000 los nuevos casos de cáncer cervical cada año.

Acerca de Roche
Roche, cuya sede central se halla en Basilea (Suiza), es una compañía líder del sector de la salud, centrada en la investigación y con la potencia combinada de la integración farmacéutica-diagnóstica. Roche es la mayor empresa biotecnológica del mundo y tiene medicamentos auténticamente diferenciados en las áreas de oncología, virología, inflamación, metabolismo y sistema nervioso central. Roche también es el líder mundial en diagnóstico in vitro, incluido el diagnóstico histológico del cáncer, y pionero en el control de la diabetes. La estrategia de Roche en medicina personalizada tiene como fin proporcionar medicamentos y herramientas diagnósticas que hagan posible mejoras tangibles de la salud, la calidad de vida y la esperanza de vida de los pacientes. En el año 2011, Roche tenía más de 80.000 empleados en todo el mundo e invirtió más de 9.000 millones de francos suizos en investigación y desarrollo. Las ventas alcanzaron la cifra de 42.500 millones de francos suizos. Genentech (Estados Unidos) es un miembro de plena propiedad del Grupo Roche. Roche posee una participación mayoritaria en Chugai Pharmaceutical (Japón). Para más información: www.roche.com.

Todas las marcas comerciales utilizadas o mencionadas están protegidas por la ley.

Para consultas de medios, contacte:
888-545-2443

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
The world's leading Cloud event, Cloud Expo has launched Microservices Journal on the SYS-CON.com portal, featuring over 19,000 original articles, news stories, features, and blog entries. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. Microservices Journal offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. Follow new article posts on Twitter at @MicroservicesE
SYS-CON Events announced today that Litmus Automation will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Litmus Automation’s vision is to provide a solution for companies that are in a rush to embrace the disruptive Internet of Things technology and leverage it for real business challenges. Litmus Automation simplifies the complexity of connected devices applications with Loop, a secure and scalable cloud platform.
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, will discuss how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at the same time reduce Time to Market (TTM) by using plug and play capabilities offered by a robust I...
SYS-CON Events announced today the IoT Bootcamp – Jumpstart Your IoT Strategy, being held June 9–10, 2015, in conjunction with 16th Cloud Expo and Internet of @ThingsExpo at the Javits Center in New York City. This is your chance to jumpstart your IoT strategy. Combined with real-world scenarios and use cases, the IoT Bootcamp is not just based on presentations but includes hands-on demos and walkthroughs. We will introduce you to a variety of Do-It-Yourself IoT platforms including Arduino, Raspberry Pi, BeagleBone, Spark and Intel Edison. You will also get an overview of cloud technologies s...
Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 16th Cloud Expo at the Javits Center in New York June 9-11 will find fresh new content in a new track called PaaS | Containers & Microservices Containers are not being considered for the first time by the cloud community, but a current era of re-consideration has pushed them to the top of the cloud agenda. With the launch of Docker's initial release in March of 2013, interest was revved up several notches. Then late last...
The WebRTC Summit 2014 New York, to be held June 9-11, 2015, at the Javits Center in New York, NY, announces that its Call for Papers is open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 16th International Cloud Expo, @ThingsExpo, Big Data Expo, and DevOps Summit.
SOA Software has changed its name to Akana. With roots in Web Services and SOA Governance, Akana has established itself as a leader in API Management and is expanding into cloud integration as an alternative to the traditional heavyweight enterprise service bus (ESB). The company recently announced that it achieved more than 90% year-over-year growth. As Akana, the company now addresses the evolution and diversification of SOA, unifying security, management, and DevOps across SOA, APIs, microservices, and more.
Wearable technology was dominant at this year’s International Consumer Electronics Show (CES) , and MWC was no exception to this trend. New versions of favorites, such as the Samsung Gear (three new products were released: the Gear 2, the Gear 2 Neo and the Gear Fit), shared the limelight with new wearables like Pebble Time Steel (the new premium version of the company’s previously released smartwatch) and the LG Watch Urbane. The most dramatic difference at MWC was an emphasis on presenting wearables as fashion accessories and moving away from the original clunky technology associated with t...
SYS-CON Events announced today that robomq.io will exhibit at SYS-CON's @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. robomq.io is an interoperable and composable platform that connects any device to any application. It helps systems integrators and the solution providers build new and innovative products and service for industries requiring monitoring or intelligence from devices and sensors.
The list of ‘new paradigm’ technologies that now surrounds us appears to be at an all time high. From cloud computing and Big Data analytics to Bring Your Own Device (BYOD) and the Internet of Things (IoT), today we have to deal with what the industry likes to call ‘paradigm shifts’ at every level of IT. This is disruption; of course, we understand that – change is almost always disruptive.
SYS-CON Events announced today that Solgenia will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY, and the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Solgenia is the global market leader in Cloud Collaboration and Cloud Infrastructure software solutions. Designed to “Bridge the Gap” between Personal and Professional Social, Mobile and Cloud user experiences, our solutions help large and medium-sized organizations dr...
SYS-CON Events announced today that SafeLogic has been named “Bag Sponsor” of SYS-CON's 16th International Cloud Expo® New York, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. SafeLogic provides security products for applications in mobile and server/appliance environments. SafeLogic’s flagship product CryptoComply is a FIPS 140-2 validated cryptographic engine designed to secure data on servers, workstations, appliances, mobile devices, and in the Cloud.
After making a doctor’s appointment via your mobile device, you receive a calendar invite. The day of your appointment, you get a reminder with the doctor’s location and contact information. As you enter the doctor’s exam room, the medical team is equipped with the latest tablet containing your medical history – he or she makes real time updates to your medical file. At the end of your visit, you receive an electronic prescription to your preferred pharmacy and can schedule your next appointment.
GENBAND has announced that SageNet is leveraging the Nuvia platform to deliver Unified Communications as a Service (UCaaS) to its large base of retail and enterprise customers. Nuvia’s cloud-based solution provides SageNet’s customers with a full suite of business communications and collaboration tools. Two large national SageNet retail customers have recently signed up to deploy the Nuvia platform and the company will continue to sell the service to new and existing customers. Nuvia’s capabilities include HD voice, video, multimedia messaging, mobility, conferencing, Web collaboration, deskt...
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
SYS-CON Events announced today that Cisco, the worldwide leader in IT that transforms how people connect, communicate and collaborate, has been named “Gold Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Cisco makes amazing things happen by connecting the unconnected. Cisco has shaped the future of the Internet by becoming the worldwide leader in transforming how people connect, communicate and collaborate. Cisco and our partners are building the platform for the Internet of Everything by connecting the...
Temasys has announced senior management additions to its team. Joining are David Holloway as Vice President of Commercial and Nadine Yap as Vice President of Product. Over the past 12 months Temasys has doubled in size as it adds new customers and expands the development of its Skylink platform. Skylink leads the charge to move WebRTC, traditionally seen as a desktop, browser based technology, to become a ubiquitous web communications technology on web and mobile, as well as Internet of Things compatible devices.
Docker is an excellent platform for organizations interested in running microservices. It offers portability and consistency between development and production environments, quick provisioning times, and a simple way to isolate services. In his session at DevOps Summit at 16th Cloud Expo, Shannon Williams, co-founder of Rancher Labs, will walk through these and other benefits of using Docker to run microservices, and provide an overview of RancherOS, a minimalist distribution of Linux designed expressly to run Docker. He will also discuss Rancher, an orchestration and service discovery platf...
SYS-CON Events announced today that Vitria Technology, Inc. will exhibit at SYS-CON’s @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Vitria will showcase the company’s new IoT Analytics Platform through live demonstrations at booth #330. Vitria’s IoT Analytics Platform, fully integrated and powered by an operational intelligence engine, enables customers to rapidly build and operationalize advanced analytics to deliver timely business outcomes for use cases across the industrial, enterprise, and consumer segments.
SYS-CON Events announced today that Liaison Technologies, a leading provider of data management and integration cloud services and solutions, has been named "Silver Sponsor" of SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York, NY. Liaison Technologies is a recognized market leader in providing cloud-enabled data integration and data management solutions to break down complex information barriers, enabling enterprises to make smarter decisions, faster.